Society of Infectious Diseases Pharmacists

PrecisePK Celebrates 30 Years of Bayesian Precision Dosing Partnership With UC San Diego Health, Leading Other UC Hospitals To Follow

Retrieved on: 
Thursday, August 24, 2023
Partnership, Society, Infectious Diseases Society of America, Tacrolimus, Jacobs Medical Center, Rady Children's Hospital, Software, Infection, Survival, Society of Infectious Diseases Pharmacists, Cancer, UC San Diego Health, Pharmacokinetics, Staphylococcus aureus, AKI, Pharmacist, Aminoglycoside, Hospital, Vancomycin, UC, Guideline, Patient, Patient safety, SAN, AUC, Busulfan, Scripps Health, Pharmacology, Safety, American Society of Health-System Pharmacists, Pharmaceutical industry, Generic drug, Medical imaging, List of things named after Thomas Bayes

SAN DIEGO, Aug. 24, 2023 /PRNewswire/ -- Today, PrecisePK announces the celebration of the 30th anniversary of its partnership with UC San Diego Health.

Key Points: 
  • SAN DIEGO, Aug. 24, 2023 /PRNewswire/ -- Today, PrecisePK announces the celebration of the 30th anniversary of its partnership with UC San Diego Health.
  • This decades-long initiative has proven the success of using Bayesian precision dosing to improve patient outcomes.
  • With other UC hospitals joining, PrecisePK is delivering state-of-the-art Bayesian therapeutic drug monitoring technology to a total of 9 prominent sites.
  • PrecisePK and UCSD Health mark 30 years of partnership in vancomycin AUC precision dosing, leading others to follow.

New England Life Care Selects DoseMe to Support New Initiatives Around Compliance Protocols

Retrieved on: 
Thursday, August 3, 2023
Nursing, Health, Hospitals, Health Technology, General Health, Pharmaceutical, Society, Nephrotoxicity, Infection, Society of Infectious Diseases Pharmacists, IDSA, CCO, Aminoglycoside, Hospital, Vancomycin, NELC, American Society of Health-System Pharmacists, Patient, Patient safety, AUC, Medicine, PIDS, Infectious Diseases Society of America, ASHP, TDM, Software, Medical device, Pharmacy, Dosem

New England Life Care is nationally recognized as a nonprofit, mission-driven home infusion therapy and specialty pharmacy services provider affiliated with 60+ of New England’s premier medical centers.

Key Points: 
  • New England Life Care is nationally recognized as a nonprofit, mission-driven home infusion therapy and specialty pharmacy services provider affiliated with 60+ of New England’s premier medical centers.
  • “As a home infusion pharmacy, NELC wanted to make sure we were prepared to support our member hospitals when instituting new procedures and protocols related to the new vancomycin guidelines, released in 2020,” stated Erica Sievert, Regional Director of Pharmacy for New England Life Care.
  • New England Life Care is using DoseMeRx’s clinical decision support software to dose vancomycin and aminoglycosides.
  • “We are thrilled to be working with the team at New England Life Care to better serve their patients while staying ahead of guidelines and protocols,” said John Hardesky, CCO of DoseMe.

Kern Medical Chooses PrecisePK to Provide Bayesian Precision Dosing Solutions

Retrieved on: 
Thursday, May 25, 2023
BCPS, Society, Infectious Diseases Society of America, MIC, Doctor of Pharmacy, Partnership, Kern Medical Center, Staphylococcus, OPAT, Education, Workflow, Society of Infectious Diseases Pharmacists, Infection, ID, Pharmacist, Vancomycin, Patient, SAN, Microsoft Excel, AUC, Knowledge, UCLA, American Society of Health-System Pharmacists, Pharmaceutical industry, List of things named after Thomas Bayes

SAN DIEGO, May 25, 2023 /PRNewswire/ -- Today, PrecisePK welcomes Kern Medical as its latest institution to implement innovations in precision dosing for vancomycin and other antibiotics using the Bayesian AUC-based method.

Key Points: 
  • SAN DIEGO, May 25, 2023 /PRNewswire/ -- Today, PrecisePK welcomes Kern Medical as its latest institution to implement innovations in precision dosing for vancomycin and other antibiotics using the Bayesian AUC-based method.
  • This recent alliance with Kern Medical adds to the system-wide endeavor of accomplishing personalized and precision dosing with a modernized approach by leveraging technology.
  • Kern Medical's vancomycin dosing workflow is standardized and improved by PrecisePK's Bayesian precision dosing tools.
  • With Bayesian precision dosing, it's more than the right dose for the right patient at the right time.

Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022

Retrieved on: 
Wednesday, October 19, 2022
RNA transfection, Pharmacist, National, Walter, Society of Infectious Diseases Pharmacists, Infectious Diseases Society of America, DNA, Solution, Epidemiology, Enactment, NYSE, MPH, Makerere University, Private Securities Litigation Reform Act, Company, JN-International Medical Corporation, LNC, PIDS, Cryptococcosis, GLOBE, Consultant, Hoffmann-La Roche, Amikacin, Infectious Diseases Institute, Diagnosis, Vaccine, Boulware, Walter E. Washington Convention Center, Research, Gilead Sciences, Technology, BioNTech, HIV, Organic acid, IDSA, Form 10-K, Washington Convention Center, Risk, Sale, SEC, Society, Patient, Infection, Partnership, Forward-looking statement, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery, Genentech, MD

Atukunda and Boulware will present the EnACT Phase 2 abstract on Friday, October 21st at the Walter E. Washington Convention Center, in Washington DC.

Key Points: 
  • Atukunda and Boulware will present the EnACT Phase 2 abstract on Friday, October 21st at the Walter E. Washington Convention Center, in Washington DC.
  • IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP).
  • Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology.
  • Matinas BioPharmas product candidates are all in a development stage and are not available for sale or use.

Infectious Disease Connect Shares New Infectious Diseases Data and Insights at IDWeek™ 2022

Retrieved on: 
Wednesday, October 19, 2022
Physician, Doctor of Pharmacy, Efficiency, Infection, Academic Medical Center (Amsterdam), University, Society of Infectious Diseases Pharmacists, Patient, Pharmacist, Research, Comparison, ASP, Technology, Precision medicine, Antimicrobial stewardship, Impact, Community hospital, Society, Association, Insight, GLOBE, UPMC, Hospital, Infectious Diseases Society of America, Data science, Documentation, Pharmaceutical industry, D.C, Woman

ID Connects corporate values start by putting patients first, said Dave Zynn, president, and chief executive officer of ID Connect.

Key Points: 
  • ID Connects corporate values start by putting patients first, said Dave Zynn, president, and chief executive officer of ID Connect.
  • IDWeek uniquely unites infectious diseases clinicians,investigators, and infection preventionists to explore current developments in the field of Infectious Diseases (ID).
  • Sponsored bythe Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, HIV Medicine Association, Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists, this annual meeting bridges the fields of real-world ID clinical practiceand research.
  • 1 Division of Infectious Diseases, UPMC
    ID Connect is a world leader in telemedicine-enabled care of infectious diseases, antimicrobial stewardship, and infection control and prevention.

Qpex Biopharma Announces Presentations on Phase 1 and Nonclinical Data on Three Clinical Stage Oral and IV Products Targeting Antibiotic-Resistant Bacterial Infections at 2022 ID Week Meeting

Retrieved on: 
Monday, October 17, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, LinkedIn, Doctor of Pharmacy, CDC, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Office of Inspector General, U.S. Department of Health and Human Services, PD, Society of Infectious Diseases Pharmacists, Infection, Biopharma LLC, Pharmacist, Twitter, Partnership, WHO, BARDA, World, Acinetobacter, Acinetobacter baumannii, Aivo Orav, Society, Pseudomonas aeruginosa, Health, PIDS, OTA, Infectious Diseases Society of America, Beta-lactam, World Health Organization, Lipopeptide, IDSA, Pharmacokinetics, Drug of last resort, ID, ESBL, Pharmaceutical industry, Hospital, Tolerability, Pseudomonas, FIDSA, Safety

Qpex Biopharma today announced that clinical and preclinical data on its portfolio of clinical stage investigational antibiotic programs will be featured in several presentations at the upcoming 2022 ID Week Meeting in Washington, DC on October 19-23.

Key Points: 
  • Qpex Biopharma today announced that clinical and preclinical data on its portfolio of clinical stage investigational antibiotic programs will be featured in several presentations at the upcoming 2022 ID Week Meeting in Washington, DC on October 19-23.
  • The presentations will describe progress on three Qpex investigational products that the recent WHO pipeline analysis identified as addressing drug-resistant pathogens for which there is a critical need for new drugs.
  • QPX9003: a next-generation, IV-administered synthetic lipopeptide with an enhanced therapeutic profile designed to focus on highly drug-resistant infections caused by Pseudomonas and Acinetobacter.
  • The company also has a partnership with Brii Biosciences for the development and commercialization of three of its products in greater China.

HealthTrackRx Announces the Formation of Clinical Advisory Board with Leading Experts in Infectious Disease and Antimicrobial Resistance

Retrieved on: 
Thursday, October 13, 2022
Doctor of Pharmacy, Laboratory, Mayo Clinic, Infection, COVID, FACP, Tufts University, Pharmacist, Infectious Diseases Society of America, PCR, University, Treatment, Health, Society of Infectious Diseases Pharmacists, Pathology, Molecule, FCCP, AMR, Transplant, Individualized medicine, P, Industry, ARUP Laboratories, MHS, MACP, Summa Health, Duke University, Northeast Ohio Medical University, Society, NIH, Immunodeficiency, IDSA, ID, Master of Science, Dedicated hosting service, ASCP, Community-acquired pneumonia, Patient, American Society for Microbiology, Doctor of Philosophy, Research, Associate, Center, Pharmaceutical industry, Vaccine, Medicine, Microbiology, FIDSA, MD

DENTON, Texas, Oct. 13, 2022 /PRNewswire/ --HealthTrackRx, the nation's premier PCR diagnostic testing laboratory, today announced the formation of its Clinical Advisory Board, comprising of leading clinical experts who specialize in infectious disease (ID) and antimicrobial resistance (AMR).

Key Points: 
  • DENTON, Texas, Oct. 13, 2022 /PRNewswire/ --HealthTrackRx, the nation's premier PCR diagnostic testing laboratory, today announced the formation of its Clinical Advisory Board, comprising of leading clinical experts who specialize in infectious disease (ID) and antimicrobial resistance (AMR).
  • "We are thrilled to have these world-renowned infectious disease and antimicrobial resistance experts on our Clinical Advisory Board.
  • Insights from our Clinical Advisory Board members can help us transform infectious disease diagnostics to improve patient care, reduce healthcare costs, and combat the looming threat of antimicrobial resistance."
  • HealthTrackRx is the nation's leading PCR-based infectious disease laboratory, delivering industry-leading testing turnaround times to healthcare providers nationwide.

Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022

Retrieved on: 
Thursday, October 13, 2022
Infection, Private Securities Litigation Reform Act, Food and Drug Administration Amendments Act of 2007, Susceptibility, NASDAQ, CDI, Pharmacist, Nasdaq, Treatment, Next Stage with You, Society of Infectious Diseases Pharmacists, Journal, Commensalism, Infectious Diseases Society of America, Vancomycin, Safety, Poster, Quality of life, Randomness, SMMT, Knowledge, Company, Marketing, Summit, PIDS, GLOBE, Clinical trial, The Journal of Infectious Diseases, Ridinilazole, Research, Security (finance), Giovanni, Trial of the century, U.S. Securities and Exchange Commission, IDSA, Diarrhea, Risk, Clostridioides difficile (bacteria), Patient, Clostridioides difficile infection, Coronavirus, Food, Efficacy, Society, Recurrence, COVID-19, Epidemiology, Pharmaceutical industry, Vaccine, Medical device, Clostridium, Clostridioides, DRS

Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) and its product candidate, ridinilazole, will have an oral podium presentation and a poster presentation at IDWeek 2022.

Key Points: 
  • Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) and its product candidate, ridinilazole, will have an oral podium presentation and a poster presentation at IDWeek 2022.
  • In the Ri-CoDIFy study, ridinilazole resulted in a meaningful reduction in the rate of recurrence of C. diff.
  • infection (8.1% vs 17.3%) and achieved a numerically higher sustained clinical response1 rate (73.0% vs 70.7%) than vancomycin.
  • We are pleased to inform that the results of our clinical study validated the assertions of Drs.

Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022

Retrieved on: 
Wednesday, October 12, 2022
RNA transfection, Adult, Pharmacist, National, Walter, Society of Infectious Diseases Pharmacists, Infectious Diseases Society of America, University of Minnesota, DNA, Solution, Epidemiology, Enactment, NYSE, MPH, Makerere University, Amphotericin B, Private Securities Litigation Reform Act, Company, LNC, Mycosis, PIDS, Cryptococcosis, GLOBE, Consultant, Hoffmann-La Roche, Amikacin, Infectious Diseases Institute, Diagnosis, Vaccine, Walter E. Washington Convention Center, Research, Gilead Sciences, Technology, BioNTech, HIV, Organic acid, IDSA, ID, Form 10-K, Washington Convention Center, Risk, Physician, Sale, Harbor–UCLA Medical Center, SEC, ABC, Patient, Infection, Partnership, Society, Abstract (summary), Forward-looking statement, Mucormycosis, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery, Genentech, MD

BEDMINSTER, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform delivery technology, today announced three upcoming oral data presentations during IDWeek 2022, the premier U.S. meeting of leaders in the field of infectious diseases taking place in-person at the Walter E. Washington Convention Center, in Washington DC from October 19-23, 2022.

Key Points: 
  • The data from these three presentations provide a deeper understanding of MAT2203s safety profile and impressive efficacy against two of the deadliest invasive fungal infections in cryptococcal meningitis and mucormycosis, said Theresa Matkovits, Ph.D., Chief Development Officer of Matinas BioPharma .
  • Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology.
  • The Company is focused on developing an internal and external pipeline of drugs candidates based on the LNC platform.
  • Matinas BioPharmas product candidates are all in a development stage and are not available for sale or use.

Children's Hospital Colorado Measures How Antibiotics are Prescribed to Patients in Hospitals Across Colorado

Retrieved on: 
Wednesday, September 7, 2022
Aurora, Partnership, Pharmacist, Sex, UC, Program, Roger Hawkins (drummer), Time, YouTube, News, Public health, Joint Commission, Colorado Department of Public Health and Environment, Children's Hospital Colorado, Pediatrics, Antimicrobial stewardship, Infection, Anschutz Medical Campus, Review, Education, Hospital, Method, Disability, UC Davis Medical Center, Surgeon, Health, Instagram, Leadership, Doctor of Public Health, CH, Center, Society of Infectious Diseases Pharmacists, Population, Communication, Twitter, Color, American Society of Health-System Pharmacists, Adult, Nursing, Risk, Children's Hospital, Profile, Society, CDC, Family, Patient, Medicine, Antibiotics, Pharmaceutical industry, S4, Child, MD, Facebook

AURORA, Colo., Sept. 7, 2022 /PRNewswire/ -- Children's Hospital Colorado (Children's Colorado) announced today a Colorado collaboration on antimicrobial stewardship and best practices for hospitals to improve the optimization and use of antibiotics leading to better pediatric patient outcomes.

Key Points: 
  • AURORA, Colo., Sept. 7, 2022 /PRNewswire/ -- Children's Hospital Colorado (Children's Colorado) announced today a Colorado collaboration on antimicrobial stewardship and best practices for hospitals to improve the optimization and use of antibiotics leading to better pediatric patient outcomes.
  • Of the 100 surveys sent to hospitals, 41 responded about their stewardship program implementation.
  • This partnership with Children's Hospital Colorado has allowed us to quantify resource needs in Colorado community hospitals.
  • "There is an opportunity for Children's Colorado to help educate pharmacists to review antibiotics being prescribed to make sure they are correct for treating pediatric patients."